NIH R01 · 2025
Abstract HER2-positive (HER2+) and triple negative breast cancer (TNBC) are the most aggressive clinical breast cancer subtypes and share similar treatment approaches and unmet needs. Both are treated with either anti- HER2 drugs (for HER2+), or immunotherapy (for TNBC), added to polychemotherapy prior to surgery, called “neoadjuvant” therapy. Residual disease (RD) at surgery is seen in 45% of HER2+ and 35% of TNBC and carries a significantly poorer prognosis. For this reason, both HER2+ and TNBC receive additional therapy postoperatively ("adjuvantly"), namely an anti-HER2 antibody-drug conjugate (ADC) in HER2+, and additional chemotherapy added to ongoing immunotherapy in TNBC. This…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.